Olaparib
References
- Martin, Niall Morrison Barr; Smith, Graeme Cameron Murray; Jackson, Stephen Philip; Loh, Vincent M., Jr.; Cockcroft, Xiao-Ling Fan; Matthews, Ian Timothy Williams; Menear, Keith Allan; Kerrigan, Frank; Ashworth, Alan, Phthalazinone Derivatives, EP1633724B1, May 4, 2011
- Sparidans, Rolf W.; Martens, Irene; Valkenburg-van Iersel, Liselot B. J.; den Hartigh, Jan; Schellens, Jan H. M.; Beijnen, Jos H., Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Volume: 879, Issue: 21, Pages: 1851-1856, 2011
Frequently Asked Questions
Can impurities in Olaparib be eliminated?
It's difficult to remove all impurities from any pharmaceutical product, including Olaparib. Manufacturers work hard to reduce impurities through optimized synthesis procedures, purification techniques, and quality control. The goal is to maintain impurity levels considerably below the permissible limits set by regulatory bodies to assure the drug's safety and efficacy.
How are Olaparib impurities formed?
Impurities might occur as unexpected byproducts or side reactions during the production of Olaparib. They can emerge as a result of incomplete reaction conditions, chemical transformations, or the usage of impure starting materials.
Why are Olaparib impurities a concern?
Impurities in Olaparib may impair its efficacy, safety, and overall quality. They must be regulated and monitored to ensure purity and the drug's efficacy.
What are the temperature conditions required to store Olaparib impurities?
Olaparib Impurities should be stored at a regulated room temperature of 2-8°C or as specified on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.